Search
Biotech CEO Sisterhood: As CEO, Sophie Kornowski sold Boston Pharmaceuticals to GSK earlier this year for up to $2 billion. She shares her thoughts on the biopharma business and leadership
Interviewed by Sisterhood editorial board member Daphne Zohar, Sophie Kornowski shares her keys to creating great assets,...
Jul 18, 2025
Prime Medicine's new CEO Allan Reine walks us through the prime editing company's new focused pipeline
He describes the benefits of prime editing, walks us through human proof-of-concept data that was announced in a patient with Chronic...
Jul 17, 2025
Kailera Therapeutics' partner Hengrui announced positive p3 results for its GLP1/GIP agonist in China - biotech veteran and Kailera CEO Ron Renaud walks us through the company's obesity space strategy
He describes why Kailera chose to in-license a GLP1/GIP specifically, and describes where he sees this asset placing in the competitive...
Jul 16, 2025
Southampton professor, and Curve Therapeutics' CSO, Ali Tavassoli describes the unique properties of cyclic peptides and why he believes Curve's cell-based method to drug discovery makes it different
He describes the properties that make cyclic peptides unique compared to small molecules and antibodies, and how Curve's approach is...
Jul 15, 2025
Southampton, UK based Curve Therapeutics believes its mammalian cell-based 'Microcycle' platform is a better way to do drug discovery - lead programs from it target HIF-1/HIF-2 and ATIC
Co-Founder and CEO Simon Kerry discusses being in Southampton, and why he believes the 'Microcycle' platform beats screening in...
Jul 15, 2025
Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)
Jorge Santos da Silva walks us through the scientific design of the molecule, which is a nanobody that binds to IL-17A, IL-17F, and...
Jul 10, 2025
KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks
Ben Palleiko is asked about the company's take on headlines that were in the news during the FDA review of the drug, and he describes the...
Jul 7, 2025
AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery
Co-Founder & CEO Peter Fedichev describes why he believes reading the amino acid sequences that have been written into the human genome...
Jun 30, 2025
BioVenture VoiCes Episode 22: Adjuvant Capital's Glenn Rockman
Glenn Rockman describes the introduction to impact investing he gained from working for J.P. Morgan and along with the Gates Foundation...
Jun 30, 2025
Off-Target Effects Episode 4: Matt speaks with Philip Ross, one of the most experienced and successful bankers in healthcare, about the M&A landscape and his decision to join Jefferies last year
Philip Ross talks about the outlook for M&A in our industry, and describes the pharma revenue growth demands that will be driving it. He...
Jun 30, 2025
Jones Research analyst Catherine Novack discusses Capricor's regulatory roller coaster, RNA editing, and more
She gives a scenario analysis in the event that FDA asked Capricor for more data rather than approving the therapy by its August 31st...
Jun 27, 2025
ArsenalBio's Co-Founder & CEO Ken Drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features
He describes the ArsenalBio's "CITE" platform, which allows it to make heterogenous cells by inserting modifications all in the same...
Jun 27, 2025
Discussing hot button issues for biotech, and how they do or don't affect the mechanics of M&A, with one of the most experienced bankers in healthcare, Jefferies' Philip Ross
He describes how some front and center issues for biotech either do or don't affect the M&A environment such as China, negative enterprise values, the FTC, valuations, the patent cliff, and more.
Jun 27, 2025
William Blair biotech analyst Andy Hsieh takes stock of the obesity space after attending the 2025 American Diabetes Association's (ADA's) 85th Scientific Sessions in Chicago
He discusses data presented at #ADA25 including Eli Lillys Orforglipron and Bimagrumab, Novo Nordisk's CagriSema, and Amgen's MariTide....
Jun 26, 2025
Checking in with the co-founders of Amylyx Pharmaceuticals, which now has one program in pivotal, another that may start soon, and earlier stage clinical programs that will have data this year
Josh Cohen and Justin Klee walk us through the lead program, avexitide, which is a GLP-1 antagonist and is currently in a pivotal study...
Jun 25, 2025
Oxford, UK based Pathios Therapeutics is targeting GPR65 for cancer, a signaling pathway that becomes active in the low pH tumor microenvironment and causes immunosuppression and high angiogenesis
CEO Paul Higham describes the biology of GPR65 inhibition, something that pharma companies have previously tried to do, and explains how...
Jun 24, 2025
AI News: Emeryville based Fauna Bio launched Fauna Brain, an AI platform that uses both internal and external data sets, and an analysis of the literature, to allow users to identify and score targets
Co-Founder Linda Goodman describes the product and the numerous components that go into the scoring.
Jun 20, 2025
The Co-Director of Cardiff University's Medicines Discovery Institute talks about the specialized work that happens here in neuroscience, cancer, and beyond
Simon Ward, Co-Director along with John Atack, describes the founding of the institue and why Cardiff University was a good fit. He...
Jun 20, 2025
SV Health Investors Managing Partner Kate Bingham shares the firm's investment philosophy and gives her take on the current state of life sciences in the United Kingdom and beyond
Kate Bingham describes the type of investments SV makes, which was in the news this week for being the founding investor of the...
Jun 20, 2025
AI News: Alameda based Infinimmune launched its GLIMPSE-1 antibody engineering platform that is based on a protein language model focused on native human antibody sequences
Co-Founder and CEO Wyatt McDonnell describes why Infinimmune believes that learning directly from the human adaptive immune system is an...
Jun 19, 2025
.png){kind=logo}
